«Our combined findings demonstrate that p53 status represents a critical determinant in selection of therapeutic strategies for
lung adenocarcinoma patients.»
They found that 64 percent of
lung adenocarcinoma patients had at least one oncogenic driver gene.
Not exact matches
In
patient samples of
lung adenocarcinoma, 3 percent were found to have HER2 amplification and another 3 percent were found to have HER2 mutation.
Likewise, an analysis tissue samples from
patients with
lung adenocarcinoma with no or low C / EBPα expression revealed that those with lower levels of BMI1 were more likely to survive, a pattern that has prognostic value, the researchers wrote.
Drs. Ana Robles, Delphine Lissa, Curtis Harris, and collaborators at the National Cancer Institute in Bethesda, Maryland, sought prognostic biomarkers that could predict relapse in
patients with stage I
lung adenocarcinoma, a major subtype of NSCLC.
Validation of a cell cycle progression score for five - year mortality risk in
patients with stage I
lung adenocarcinoma.
«It is quite striking that we have now identified an actionable mutation in over 75 percent of
patients with
lung adenocarcinoma, a significant improvement from a decade ago,» said Meyerson.
We will identify where the guideline strengthens or reaffirms the 2013 recommendations for
patients with
lung adenocarcinoma, as well recommendations for testing for several new genes.